HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rhian M Touyz Selected Research

sodium-magnesium antiporter

2/2003Inhibitors of Na+/Mg2+ exchange activity attenuate the development of hypertension in angiotensin II-induced hypertensive rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rhian M Touyz Research Topics

Disease

147Hypertension (High Blood Pressure)
01/2022 - 01/2002
48Inflammation (Inflammations)
01/2022 - 12/2002
30Cardiovascular Diseases (Cardiovascular Disease)
10/2020 - 06/2002
22Vascular Remodeling
10/2021 - 01/2002
20Fibrosis (Cirrhosis)
01/2022 - 06/2002
18Stroke (Strokes)
03/2022 - 01/2002
17Vascular System Injuries
01/2022 - 05/2003
15Albuminuria
01/2022 - 06/2005
14Neoplasms (Cancer)
01/2022 - 10/2009
14Heart Failure
01/2021 - 06/2005
13Diabetes Mellitus
12/2019 - 02/2004
12Diabetic Nephropathies (Diabetic Nephropathy)
01/2022 - 06/2009
12Body Weight (Weight, Body)
12/2018 - 08/2003
12Hypertrophy
01/2017 - 05/2003
10Myocardial Infarction
10/2021 - 06/2005
10Obesity
12/2018 - 06/2003
9Chronic Renal Insufficiency
01/2016 - 06/2005
7Atherosclerosis
01/2021 - 05/2013
7Cardiomegaly (Heart Hypertrophy)
01/2020 - 10/2003
7Insulin Resistance
12/2018 - 06/2003
6COVID-19
01/2022 - 01/2020
6Vascular Diseases (Vascular Disease)
01/2020 - 03/2005
6Hyperaldosteronism (Conn Syndrome)
01/2019 - 02/2005
6Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2016 - 02/2007
6Isolated Systolic Hypertension
05/2010 - 06/2005
5Pre-Eclampsia (Preeclampsia)
01/2022 - 05/2004
5Cerebrovascular Disorders (Cerebrovascular Occlusion)
12/2019 - 05/2007
5Type 2 Diabetes Mellitus (MODY)
12/2018 - 02/2004
5Vascular Calcification
01/2018 - 02/2009
4Chronic Disease (Chronic Diseases)
10/2022 - 02/2009
4Thrombosis (Thrombus)
03/2021 - 01/2016
4Hyperglycemia
09/2020 - 10/2009
4Dyslipidemias (Dyslipidemia)
09/2020 - 06/2005
4Necrosis
01/2020 - 10/2012
4Magnesium Deficiency (Deficiency, Magnesium)
07/2011 - 05/2004
3CADASIL
01/2021 - 11/2019
3Cardiac Arrhythmias (Arrythmia)
01/2021 - 01/2020

Drug/Important Bio-Agent (IBA)

46Reactive Oxygen Species (Oxygen Radicals)IBA
01/2022 - 11/2002
38Angiotensin IIIBA
01/2022 - 10/2002
25NADPH Oxidases (NAD(P)H oxidase)IBA
01/2020 - 12/2002
24SaltsIBA
01/2021 - 01/2002
21Proteins (Proteins, Gene)FDA Link
10/2021 - 11/2002
19MagnesiumIBA
10/2022 - 11/2002
17AldosteroneIBA
01/2020 - 08/2002
15AntioxidantsIBA
10/2021 - 01/2002
14Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2020 - 06/2005
13Biomarkers (Surrogate Marker)IBA
03/2022 - 05/2012
13Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 05/2014
13Phosphotransferases (Kinase)IBA
01/2021 - 11/2002
12Nitric Oxide (Nitrogen Monoxide)FDA Link
01/2021 - 08/2003
11Glucose (Dextrose)FDA LinkGeneric
01/2022 - 02/2007
11Angiotensin Receptor AntagonistsIBA
01/2020 - 06/2005
10Endothelins (Endothelin)IBA
01/2022 - 01/2003
10CollagenIBA
01/2022 - 06/2002
10Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
01/2021 - 06/2005
10Endothelin-1 (Endothelin 1)IBA
01/2020 - 06/2002
9Superoxides (Superoxide)IBA
01/2022 - 10/2003
9Antihypertensive Agents (Antihypertensives)IBA
01/2021 - 06/2002
9Protein Isoforms (Isoforms)IBA
10/2020 - 03/2009
9LipidsIBA
12/2019 - 06/2005
9Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
03/2019 - 06/2005
9CholesterolIBA
10/2015 - 06/2005
8Peptides (Polypeptides)IBA
01/2021 - 03/2005
81,4-dihydropyridine (dihydropyridine)IBA
05/2014 - 06/2005
7rho-Associated KinasesIBA
03/2022 - 04/2003
7Angiogenesis InhibitorsIBA
01/2022 - 01/2018
7AngiotensinsIBA
10/2021 - 12/2002
7ThiazidesIBA
01/2017 - 06/2005
7Calcium Channel Blockers (Blockers, Calcium Channel)IBA
05/2014 - 06/2005
6Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA
01/2016 - 02/2008
6Dietary SodiumIBA
02/2014 - 05/2007
6Desoxycorticosterone Acetate (DOCA)FDA Link
04/2007 - 01/2003
5Estrogens (Estrogen)FDA Link
01/2022 - 09/2009
5Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric
01/2021 - 08/2004
5Biological ProductsIBA
01/2020 - 10/2009
5Vasoconstrictor AgentsIBA
01/2020 - 10/2004
5CytokinesIBA
01/2020 - 05/2007
5Streptozocin (Streptozotocin)FDA Link
10/2017 - 04/2014
5DiureticsIBA
09/2013 - 05/2007
4Acetylcholine (Acetylcholine Chloride)FDA Link
03/2022 - 02/2004
4NADP (NADPH)IBA
01/2021 - 10/2005
4Fibronectins (Fibronectin)IBA
01/2020 - 02/2012
4MineralocorticoidsIBA
01/2020 - 10/2003
4CationsIBA
01/2020 - 12/2010
4G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
12/2018 - 03/2009
4AdipokinesIBA
08/2018 - 08/2014
4Interleukin-6 (Interleukin 6)IBA
01/2017 - 12/2013
4CalciumIBA
11/2016 - 02/2005
4Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA
11/2016 - 05/2007
4Spironolactone (Aldactone)FDA LinkGeneric
10/2015 - 07/2003
4Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
04/2015 - 02/2009
4Desoxycorticosterone (Deoxycorticosterone)IBA
04/2007 - 10/2003
3Oxygen (Dioxygen)IBA
01/2022 - 04/2006
3Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/2022 - 06/2005
3Pharmaceutical PreparationsIBA
12/2021 - 10/2016
3Tyrosine (L-Tyrosine)FDA Link
01/2021 - 04/2003
3fasudil (AT 877)IBA
01/2021 - 01/2018
3Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
01/2021 - 03/2011
3Oxidoreductases (Dehydrogenase)IBA
01/2021 - 10/2011

Therapy/Procedure

37Therapeutics
12/2021 - 05/2003